Tuberculosis - Pipeline Review, H2 2013


Naperville, IL -- (SBWIRE) -- 09/06/2013 -- Reportstack, provider of premium market research reports announces the addition of Tuberculosis - Pipeline Review, H2 2013 market report to its offering
Tuberculosis - Pipeline Review, H2 2013


, 'Tuberculosis - Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Tuberculosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Tuberculosis. Tuberculosis - Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- A snapshot of the global therapeutic scenario for Tuberculosis.
- A review of the Tuberculosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Tuberculosis pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Tuberculosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Tuberculosis pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Companies Mentioned

Johnson & Johnson
Sequella, Inc.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Piramal Healthcare Limited
Achillion Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated
AVI BioPharma Inc.
Crucell N.V.
Hollis-Eden Pharmaceuticals, Inc.
Transgene SA
Summit Corporation plc
Immune Network Research Ltd.
Advinus Therapeutics Pvt. Ltd.
Snowdon Inc.
Statens Serum Institut
ImmunoBiology Limited
Recipharm AB
Pt. Bio Farma
MicuRx Pharmaceuticals, Inc.
Mondobiotech Holding AG
EpiVax, Inc.
Archivel Farma S.L.
Chimerix, Inc.
Pharminox Limited
ImmunoVaccine Technologies Inc.
Canopus BioPharma Incorporated
TVAX Biomedical, LLC
Medisyn Technologies, Inc.
Vakzine Projekt Management GmbH
Ensoltek Co., Ltd.
B&C Biopharm
GlaxoSmithKline Inc.
NeED Pharma s.r.l.
Vichem Chemie Research Ltd.
ISA Pharmaceuticals B.V.
Lipotek Pty Ltd

To view the table of contents for this market research report please visit